An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 8, 2026 - P1 | N=32 | Active, not recruiting | Sponsor: Ono Pharmaceutical Co., Ltd. | Trial completion date: Dec 2026 ➔ Jun 2027 | Trial primary completion date: Dec 2026 ➔ Jun 2027
Trial completion date • Trial primary completion date • Oncology • Pancreatic Cancer • Solid Tumor • CA 19-9
|